AU3846395A - Compositions comprising carbazoles and cyclodextrins - Google Patents
Compositions comprising carbazoles and cyclodextrinsInfo
- Publication number
- AU3846395A AU3846395A AU38463/95A AU3846395A AU3846395A AU 3846395 A AU3846395 A AU 3846395A AU 38463/95 A AU38463/95 A AU 38463/95A AU 3846395 A AU3846395 A AU 3846395A AU 3846395 A AU3846395 A AU 3846395A
- Authority
- AU
- Australia
- Prior art keywords
- carbazoles
- cyclodextrins
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94203242 | 1994-11-07 | ||
EP94203242 | 1994-11-07 | ||
PCT/EP1995/004295 WO1996014090A1 (en) | 1994-11-07 | 1995-10-31 | Compositions comprising carbazoles and cyclodextrins |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3846395A true AU3846395A (en) | 1996-05-31 |
Family
ID=8217355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU38463/95A Abandoned AU3846395A (en) | 1994-11-07 | 1995-10-31 | Compositions comprising carbazoles and cyclodextrins |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU3846395A (en) |
IL (1) | IL115885A0 (en) |
TR (1) | TR199501376A2 (en) |
WO (1) | WO1996014090A1 (en) |
ZA (1) | ZA959388B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999063967A1 (en) * | 1998-06-05 | 1999-12-16 | Dec Research | Enhanced intra vaginal devices |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
SI1334106T1 (en) | 2000-11-17 | 2006-10-31 | Takeda Pharmaceutical | Imidazole derivatives, production method thereof and use thereof |
WO2002040470A1 (en) | 2000-11-20 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Imidazole derivatives, process for their preparation and their use |
AU2002221080A1 (en) | 2000-12-08 | 2002-06-18 | Masami Kusaka | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof |
JP5456891B2 (en) | 2009-06-26 | 2014-04-02 | ノバルティス アーゲー | 1,3-disubstituted imidazolidin-2-one derivatives as CYP17 inhibitors |
JP2013508417A (en) * | 2009-10-23 | 2013-03-07 | ヘルス リサーチ インコーポレイテッド | Methods for treating androgen receptor positive cancer |
AU2011285724B2 (en) | 2010-08-04 | 2015-01-22 | Pellficure Pharmaceuticals, Inc. | Combination therapy for the treatment of prostate carcinoma |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
ES2656218T3 (en) | 2011-04-28 | 2018-02-26 | Novartis Ag | 17 alpha-hydroxylase / C17,20-lyase inhibitors |
WO2014158875A1 (en) | 2013-03-14 | 2014-10-02 | Pellficure Pharmaceuticals Inc. | Novel therapy for prostate carcinoma |
AU2015314772B2 (en) | 2014-09-12 | 2020-02-27 | Pellficure Pharmaceuticals, Inc. | Compositions and methods for treatment of prostate carcinoma |
EP3528799A1 (en) | 2016-10-24 | 2019-08-28 | Pellficure Pharmaceuticals, Inc. | Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9310635D0 (en) * | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
-
1995
- 1995-10-31 AU AU38463/95A patent/AU3846395A/en not_active Abandoned
- 1995-10-31 WO PCT/EP1995/004295 patent/WO1996014090A1/en active Application Filing
- 1995-11-06 IL IL11588595A patent/IL115885A0/en unknown
- 1995-11-06 ZA ZA959388A patent/ZA959388B/en unknown
- 1995-11-07 TR TR95/01376A patent/TR199501376A2/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999063967A1 (en) * | 1998-06-05 | 1999-12-16 | Dec Research | Enhanced intra vaginal devices |
Also Published As
Publication number | Publication date |
---|---|
IL115885A0 (en) | 1996-01-31 |
ZA959388B (en) | 1997-05-06 |
TR199501376A2 (en) | 1996-06-21 |
WO1996014090A1 (en) | 1996-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3641597A (en) | Methods and compositions comprising r-ibuprofen | |
AU3767097A (en) | Shampoo compositions and method | |
AU7564694A (en) | Erection-inducing methods and compositions | |
AU7323294A (en) | Perfluoroelastomeric compositions and methods | |
AU2517397A (en) | Document of value | |
AU2825597A (en) | Elastomer compositions and methods | |
AU5522798A (en) | Water-responsive polymer compositions and method of making the same | |
AU4261697A (en) | Compounds and methods | |
EP0690494A3 (en) | Connection and build-up-process for multi-chip-modules | |
AU4266596A (en) | Composition and use | |
AU2349399A (en) | R-lansoprazole compositions and methods | |
AU3308195A (en) | Antihypertriglyceridemic composition | |
AU2972597A (en) | Compositions and uses thereof | |
AU3846395A (en) | Compositions comprising carbazoles and cyclodextrins | |
AU5157898A (en) | Hnf3delta compositions | |
AU4425696A (en) | Polymerizable compounds and compositions | |
AU4876397A (en) | Insecticidal compositions and methods | |
AU1939895A (en) | Enzymatic debridement compositions and methods | |
AU1841195A (en) | 1-beta -methyl-carbapenem, compositions containing same and methods of use | |
AU7525496A (en) | Methods and compositions comprising glut-2 and glut-2 chimeras | |
AU1129697A (en) | Modified polyalkadiene-containing compositions | |
AU5188296A (en) | Carbopeptoids and carbonucleotoids | |
AU6619596A (en) | Compositions | |
AUPO982097A0 (en) | Methods and compositions for use therein | |
AU1468797A (en) | Ghrh-rp compositions and methods |